SPDR

The SPDR S&P 500 ETF (SPY) gained 0.7%, recovering from recent weakness while holding above closely watched technical support levels. Traders are discussing whether the rebound signals renewed buying interest or a temporary pause, with the index's ability to stay above key price levels seen as an important test for the broader market's short-term direction.

The inverse correlation between the energy sector, tracked by the Energy Select Sector SPDR Fund (XLE), and the broader stock market has reached a record high. As energy stocks climb, the rest of the market tends to move the opposite way, a divergence now at its most extreme on record. Analysts see this as a sign of how dominant oil and gas dynamics have become in shaping overall equity performance.

Biotech stocks lagged the broader market in September, with the SPDR S&P Biotech ETF (XBI) falling while the wider market held up better. Attention is now on whether retail-favored names SELLAS Life Sciences (SLS), ImmunityBio (IBRX), Vanda Pharmaceuticals (VNDA) and Iovance Biotherapeutics (IOVA) managed to escape the sector's slump. Investors are weighing whether these popular small-cap biotechs diverged from the wider sector weakness.

Investor's Business Daily is offering coverage of current stock market data across major US benchmarks, including the S&P 500, Nasdaq, Dow Jones and SPDR ETFs. The item provides investors with a snapshot of where leading indexes are trading as market participants follow price moves and track the day's activity across major US equity markets and ETFs.

A market commentary argues that the SPDR Gold MiniShares ETF (GLDM) is a fund worth buying as central banks around the world continue accumulating gold reserves. The piece links sustained official-sector gold purchases to support for bullion prices, making a low-cost gold ETF a way for retail investors to follow the same trend. Commentary of this kind typically circulates when gold prices are strong or geopolitical uncertainty is elevated.